Prospective Evaluation of the Radiographic Efficacy of Enbrel
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
It is known from the COMET-trial that patients who start Enbrel treatment early have a great
chance of reaching clinical remission and radiographic nonprogression. It is still unclear,
however, how many patients with early arthritis achieve remission and radiographic
nonprogression under the conditions of routine rheumatologic care and the local
recommendations of Enbrel treatment (pre-treatment of at least 2 DMARDs, one of them MTX).
Therefore, no robust x-ray data are available to show/demonstrate
- the average extent of x-ray damage in routine patients on Enbrel outside clinical
studies.
- if the outstanding effect on structural damage of Enbrel can be reproduced in routine
practice.
- that the 'Silent Progressor' is an issue relevant not only in clinical trials, but also
for day-to-day decision making.
- the optimal onset of Enbrel treatment in the course of the disease to prevent
radiographic damage